Drug intelligence / Profile preview

CDCA1-64 + URLC10-177

Development stage: Preclinical
Lead developer: Oncotherapy Science
Modality: Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

CDCA1-64 + URLC10-177 is a cancer peptide vaccine combination consisting of two synthetic peptides derived from cancer-testis antigens. CDCA1-64 is derived from Cell Division Cycle Associated 1 protein, while URLC10-177 is derived from URLC10 protein. Both peptides are HLA-A24 (A*24:02)-restricted epitopes designed to induce cytotoxic T lymphocyte (CTL) responses against tumor cells expressing these antigens. This combination is used in cancer immunotherapy, particularly for esophageal cancer and other solid tumors where these antigens are overexpressed.

Other names: CDCA1-64 (KYLQVVEVF) + URLC10-177 (RYCNLEGPPI)

Targets

T cell receptor recognizing Up-regulated in lung cancer 10 (URLC10)-177/HLA-A*24:02 peptide–MHC complexTCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on CDCA1-64 + URLC10-177.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDCA1-64 + URLC10-177.

Explore the full profile